Study · Measured the body's own peptide · 2020

4 results

β-Amyloid and mitochondrial-derived peptide-c are additive predictors of adverse outcome to high-on-treatment platelet reactivity in type 2 diabetics with revascularized coronary artery disease.

Ikonomidis I, Katogiannis K, Kyriakou E, Taichert M, Katsimaglis G, Tsoumani M, Andreadou I, Maratou E, Lambadiari V, Kousathana F, Papadopoulou A, Varlamos C and 6 more

Show all authors

Plotas P, Parissis J, Stamatelopoulos K, Alexopoulos D, Dimitriadis G, Tsantes AE

Journal of thrombosis and thrombolysis1 Apr 2020Cited by 13 (Europe PMC)

PMID32052315DOI10.1007/s11239-020-02060-4PepBankPUB-32052315

Publisher page PubMedAsk about this study

Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Natural levels measured4

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

01HumanEndogenous levelObservational studyOther
In 121 type 2 diabetics on clopidogrel after revascularization, blood MOTS‑c below 167 ng/ml predicted major adverse cardiac events (relative risk 3.8) over 2 years.
In plain wordsIn people with type 2 diabetes and heart disease, a low level of the body's own MOTS‑c was linked to more heart events.
Peptide
MOTS-c
Outcome
IncreaseMACE risk with low MOTS-c (< 167 ng/ml)
Study
n = 121
Comparator
Patients without low MOTS-c
Outcome group
Cardiovascular events · Cardiovascular
Measurements
relative risk
3.8
MOTS-c < 167 ng/ml
Source sentences
Summary
HPR, β-amyloid > 51 pg/ml and MOTS-c < 167 ng/ml were predictors of MACE (relative risk 3.1, 3.5 and 3.8 respectively, p < 0.05) after adjusting for confounders and medication.
1 context sentence(design, population, supporting numbers)
Summary · context
In 121 type II diabetics, treated with clopidogrel and aspirin, (93 males, mean age 67.2 years) we measured: (a) maximum platelet aggregation to adenosine diphosphate (ADP) by light transmission aggregometry (LTAmax), (b) malondialdehyde (MDA), as oxidative stress marker, (c) MOTS-c, (d) β-amyloid blood levels.
This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-3205231501
02HumanEndogenous levelObservational studyOther
In type 2 diabetics, high on-clopidogrel platelet reactivity and blood MOTS‑c showed a significant interaction in the prediction of major adverse cardiac events.
In plain wordsIn people with type 2 diabetes, high platelet reactivity and the body's own MOTS‑c level together predicted heart events.
Peptide
MOTS-c
Outcome
Not applicableInteraction of HPR and MOTS-c for MACE prediction
Study
n = 121
Outcome group
Cardiovascular events · Cardiovascular
Source sentences
Summary
There was significant interaction between HPR and β-amyloid or MOTS-c for the prediction of MACE (p < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
In 121 type II diabetics, treated with clopidogrel and aspirin, (93 males, mean age 67.2 years) we measured: (a) maximum platelet aggregation to adenosine diphosphate (ADP) by light transmission aggregometry (LTAmax), (b) malondialdehyde (MDA), as oxidative stress marker, (c) MOTS-c, (d) β-amyloid blood levels.
This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-3205231502
03HumanEndogenous levelObservational studyOther
In type 2 diabetics, high platelet reactivity together with blood MOTS‑c below 167 ng/ml carried a fourfold higher risk of major adverse cardiac events than no predictor (relative risk 4.447).
In plain wordsIn people with type 2 diabetes, high platelet reactivity plus low natural MOTS‑c was linked to about four times more heart events.
Peptide
MOTS-c
Outcome
IncreaseMACE risk with HPR and low MOTS-c (< 167 ng/ml)
Study
n = 121
Comparator
Patients without these predictors
Outcome group
Cardiovascular events · Cardiovascular
Measurements
relative risk
4.447
HPR and MOTS-c < 167 ng/ml
Source sentences
Summary
Patients with HPR and β-amyloid > 51 mg/dl or HPR and MOTS-c concentration < 167 ng/ml had a fourfold higher risk for MACE than patients without these predictors (relative risk 4.694 and 4.447 respectively p < 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
In 121 type II diabetics, treated with clopidogrel and aspirin, (93 males, mean age 67.2 years) we measured: (a) maximum platelet aggregation to adenosine diphosphate (ADP) by light transmission aggregometry (LTAmax), (b) malondialdehyde (MDA), as oxidative stress marker, (c) MOTS-c, (d) β-amyloid blood levels.
This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-3205231503
04HumanEndogenous levelObservational studyOther
In an external validation cohort of 90 patients with diabetes and coronary artery disease, the results for the predictors of major adverse cardiac events, including blood MOTS‑c, were confirmed.
In plain wordsIn a second group of 90 people with diabetes and heart disease, the link between the body's own MOTS‑c and heart events held.
Peptide
MOTS-c
Outcome
IncreaseMACE prediction confirmed in external cohort
Study
n = 90
Outcome group
Cardiovascular events · Cardiovascular
Source sentences
Summary
The above results were confirmed in an external validation cohort of 90 patients with diabetes and CAD.
1 context sentence(design, population, supporting numbers)
Summary · context
In 121 type II diabetics, treated with clopidogrel and aspirin, (93 males, mean age 67.2 years) we measured: (a) maximum platelet aggregation to adenosine diphosphate (ADP) by light transmission aggregometry (LTAmax), (b) malondialdehyde (MDA), as oxidative stress marker, (c) MOTS-c, (d) β-amyloid blood levels.
This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-3205231504

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase not statedNCT04027712

Platelet Reactivity, B-amyloid, MOTS-c and Mortality of Type II Diabetics With CAD

University of Athensn = 1201 Jan 2014 to est. 31 Dec 2021

Diabetes · Clopidogrel Resistance · Amyloid · Insulin Resistance

Trial page ClinicalTrials.govUpdated 23 Jul 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 18:17 UTC
Study results updated
Version 1
9 Oct 2026, 02:47 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.